News & Updates

Pregnant women with preconception venous thromboembolism (VTE) who have no exposure to any anticoagulant and those on low-molecular-weight heparin (LMWH) have the lowest risk of foetal adverse outcomes, reveals a study, which supports the recommendation of LMWH during pregnancy.

A triplet regimen combining the PARP inhibitor olaparib with metronomic cyclophosphamide and metformin showed favourable signals for heavily pretreated women with advanced endometrial carcinoma, the phase I/II ENDOLA study suggests.

A recent study assessing the diagnostic and management processes of polycystic ovary syndrome (PCOS) adopted by clinicians from different specialties in Singapore has found certain variations, which warrant the need for standardized workplace protocols and patient education resources.

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.